ArticleInfectious diseases and therapy2026
Using Real-World Data to Support Claim Expansion of the Cobas SARS-CoV-2 Test in Asymptomatic Testing: Data from the National Football League Occupational Surveillance Program.
Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionClinical evidence is needed for performance of novel coronavirus disease (COVID-19) molecular tests in asymptomatic populations to support regulatory decisions. To support claim expansion of a direct molecular test, clinical use and performance of the Cobas
methodsThis study leveraged real-world data from the 2020 National Football League (NFL) COVID-19 Surveillance Program during August 1, 2020-January 3, 2021. NFL players and staff from 32 clubs had nasal samples prospectively collected on a near-daily basis. Samples underwent reverse transcription polymerase chain reaction (RT-PCR) testing by a single provider across five laboratories. The study population included individuals whose samples were tested on the candidate test. A comparator algorithm was constructed based on comparator test results and clinical adjudication within the NFL program. Results from the candidate test were compared against the comparator algorithm to calculate positive and negative percent agreements (PPA and NPA). Two-sided 95% confidence intervals (CIs) for PPA and NPA were determined (Wilson score method).
resultsA total of 1776 samples were included in the final analysis. All 11 samples with positive comparator status were positive on the candidate test (PPA 100% [95% CI 74.1, 100]). Of 1765 samples with negative comparator status, 1762 were negative on the candidate test (NPA 99.8% [95% CI 99.5, 99.9]). Results were consistent when stratified by age and sex.
conclusionsBased on data collected during this occupational testing protocol, our study provides strong evidence supporting real-world performance of this test in an asymptomatic population. These findings, complemented by data from an existing clinical study, provided the totality-of-evidence that supported the US Food and Drug Administration clearance for the expanded claim of the candidate test for the qualitative detection of SARS-CoV-2 in the asymptomatic population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.